Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
Trump and Coronavirus Pandemic Final US Catastrophe 2021 - 19th Jan 21
How To Find Market Momentum Trades for Explosive Gains - 19th Jan 21
Cryptos: 5 Simple Strategies to Catch the Next Opportunity - 19th Jan 21
Who Will NEXT Be Removed from the Internet? - 19th Jan 21
This Small Company Could Revolutionize The Trillion-Dollar Drug Sector - 19th Jan 21
Gold/SPX Ratio and the Gold Stock Case - 18th Jan 21
More Stock Market Speculative Signs, Energy Rebound, Commodities Breakout - 18th Jan 21
Higher Yields Hit Gold Price, But for How Long? - 18th Jan 21
Some Basic Facts About Forex Trading - 18th Jan 21
Custom Build PC 2021 - Ryzen 5950x, RTX 3080, 64gb DDR4 Specs - Scan Computers 3SX Order Day 11 - 17th Jan 21
UK Car MOT Covid-19 Lockdown Extension 2021 - 17th Jan 21
Why Nvidia Is My “Slam Dunk” Stock Investment for the Decade - 16th Jan 21
Three Financial Markets Price Drivers in a Globalized World - 16th Jan 21
Sheffield Turns Coronavirus Tide, Covid-19 Infections Half Rest of England, implies Fast Pandemic Recovery - 16th Jan 21
Covid and Democrat Blue Wave Beats Gold - 15th Jan 21
On Regime Change, Reputations, the Markets, and Gold and Silver - 15th Jan 21
US Coronavirus Pandemic Final Catastrophe 2021 - 15th Jan 21
The World’s Next Great Onshore Oil Discovery Could Be Here - 15th Jan 21
UK Coronavirus Final Pandemic Catastrophe 2021 - 14th Jan 21
Here's Why Blind Contrarianism Investing Failed in 2020 - 14th Jan 21
US Yield Curve Relentlessly Steepens, Whilst Gold Price Builds a Handle - 14th Jan 21
NEW UK MOT Extensions or has my Car Plate Been Cloned? - 14th Jan 21
How to Save Money While Decorating Your First House - 14th Jan 21
Car Number Plate Cloned Detective Work - PY16 JXV - 14th Jan 21
Big Oil Missed This, Now It Could Be Worth Billions - 14th Jan 21
Are you a Forex trader who needs a bank account? We have the solution! - 14th Jan 21
Finetero Review – Accurate and Efficient Stock Trading Services? - 14th Jan 21
Gold Price Big Picture Trend Forecast 2021 - 13th Jan 21
Are Covid Lockdowns Bullish or Bearish for Stocks? FTSE 100 in Focus - 13th Jan 21
CONgress "Insurrection" Is Just the Latest False Flag Event from the Globalists - 13th Jan 21
Reflation Trade Heating Up - 13th Jan 21
The Most Important Oil Find Of The Next Decade Could Be Here - 13th Jan 21
Work From Home £10,000 Office Tour – Workspace + Desk Setup 2021 Top Tips - 12th Jan 21
Collect a Bitcoin Dividend Without Owning the King of Cryptos - 12th Jan 21
The BAN Hotlist trade setups show incredible success at the start of 2021, learn how you can too! - 12th Jan 21
Stocks, Bitcoin, Gold – How Much Are They Worth? - 12th Jan 21
SPX Short-term Top Imminent - 12th Jan 21
Is This The Most Exciting Oil Play Of 2021? - 12th Jan 21
Why 2021 Will Be the Year Self-Driving Cars Go Mainstream - 11th Jan 21
Gold Began 2021 With a Bang, Only to Plunge - 11th Jan 21
How to Test Your GPU Temperatures - Running Too Hot - GTX 1650 - Overclockers UK - 11th Jan 21
Life Lesson - The Early Bird Catches the Worm - 11th Jan 21
Precious Metals rally early in 2021 - 11th Jan 21
The Most Exciting Oil Stock For 2021 - 11th Jan 21
Financial Market Forecasts 2021: Navigation in Uncharted Waters - 10th Jan 21
An Urgent Message to All Conservatives, Right-Wingers and Patriots - 10th Jan 21
Despite Signs to the Contrary, Gold Price at or Near Top - 10th Jan 21 -
Ultimate Guide On The 6 Basic Types Of Index Funds - 10th Jan 21
Getting Vaccinated at TESCO - Covid-19 Vaccinations at UK Supermarket Pharmacies and Chemists - 10th Jan 21
Cheers for the 2021 Stock Market and These "Great Expectations" - 9th Jan 21
How to Plan Your Child With Better Education - 9th Jan 21
How To Find The Best Casino - 9th Jan 21
Gold Is Still a Bargain Buy - 8th Jan 20
Gold Price Set to Soar as Hyperinflation Looms - 8th Jan 21
Have Big Dreams? Here's How to Pay for Them - 8th Jan 21
Will the Fed Support Gold Prices in 2021? - 8th Jan 21
Stocks trading strategies for beginners - 8th Jan 21
Who is Buying and Selling Stocks in 2021 - 8th Jan 21
Clap for NHS Heroes 2021 as Incompetent Government Loses Control of Virus Again! - 8th Jan 21

Market Oracle FREE Newsletter

FIRST ACCESS to Nadeem Walayat’s Analysis and Trend Forecasts

Fighting Cancer Ourselves

Companies / Healthcare Sector Jul 29, 2011 - 02:19 AM GMT

By: Casey_Research

Companies

Best Financial Markets Analysis ArticleChris Wood, Casey Extraordinary Technology writes: Worldwide, tens of thousands of researchers are working feverishly on a cure for cancer, testing countless new drugs and dozens of novel approaches. Most will end up in the dustbin. But among the most promising of that small group likely to make it to market is a new type of monoclonal antibody therapy.


That may sound like a daunting scientific concept to try to wrap one’s head around, but in essence monoclonal antibodies are simple. Most of us are familiar with antibodies, the road warriors of the human body’s immune system. They’re those little Y-shaped proteins that are used to identify and neutralize foreign objects in the body (like bacteria and viruses) by binding themselves to the target – called an antigen – and killing it.

Although one antibody is generally very similar to another in structure, a small region at the tip of the protein is extremely variable – enough so that there are millions of distinct antibodies with slightly different tip structures, or antigen binding sites. This diversity allows the immune system both to recognize an equally wide variety of antigens and to come up with new responses to new types of infections.

Now, what if the body’s ability to construct antigen-specific antibodies could be harnessed in the lab? What if scientists could produce substantial amounts of a single antibody (whichever one they wanted for a particular antigen) and that antibody alone, outside of the body? What if our own capacity for fighting infection could be turned against cancer cells? Wouldn’t that be better than present chemotherapies, which willy-nilly blast diseased and healthy cells alike?

Of course it would. Making it happen is another matter.

Fortunately, many of the technical issues were resolved about 35 years ago, when Cesar Milstein, Georges Kohler, and Niels Jerne discovered how to fuse an antibody-producing cell with a cancer cell in the lab – an effort that won them the 1984 Nobel Prize in Physiology. The resulting mutant – dubbed a hybridoma – will produce large amounts of identical antibodies from a unique parent (that’s the “monoclone” part) essentially forever.

The remaining challenge was how to put monoclonal antibodies to work against cancer.

What researchers came up with was elegant: To borrow from military parlance, they would create a “smart bomb,” an antibody which – when combined with a cancer-killing drug – would detonate inside the diseased cell.

Though elementary in conception, the smart bomb was a long time in coming. First, an antibody had to be developed that would be accepted by the host and would navigate the bloodstream until it linked to a particular cancer cell. Then there would have to be a means for a potent cancer drug to be locked to it in such a way that the bond wouldn’t disintegrate along the way; such a failure would create havoc among healthy cells. Finally, the antibody would have to be able to release its piggybacked drug once it reached its target.

The payoff is huge. Not only does this form of therapy allow for much more precise targeting, it permits the use of cytotoxins (cancer-killing agents) that are 100 to 1,000 times more potent than traditional chemotherapy drugs – a toxicity that would cause far too much collateral damage if they were introduced into the body in a non-specific way.

Fighting cancer with our own built-in defense mechanisms sounds both logical and at the same time improbable, since up to now we’ve had such little luck in combating the disease ourselves.

Yet that’s the promise of this new monoclonal antibody therapy, and the good news is that today it is far down in the research pipeline. Much testing in human subjects has been done, with results among patients whose cancers were previously deemed intractable that are nothing short of spectacular.

FDA clearance has been fast-tracked. The therapy has already been granted approval at the subcommittee level, with the full agency set to rule by the end of August. The first monoclonal antibodies with novel linkage systems binding to potent cytotoxins could hit the market this year, saving lives and making fortunes for both the company that developed them and those who invested in it.

Even the most diligent investor can’t keep up with all the developments in cancer research, let alone build the knowledge necessary to understand both the promises and challenges they face. That’s what makes a subscription to Casey Extraordinary Technology invaluable; the technology team does that work. And they’ve put together a curing cancer portfolio so that you can get in on the best prospects.

© 2011 Copyright Casey Research - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules